Bajaj Healthcare

how big is Bajaj Healthcare?

As of March 2024, Bajaj Healthcare Ltd has a market capitalization of 1,662.38 Cr, with net sales of 542.60 Cr and net profit of 39.49 Cr over the last four quarters. Shareholder's funds are 278.36 Cr, and total assets amount to 743.27 Cr.

Market Cap: Bajaj Healthcare Ltd has a market capitalization of 1,662.38 Cr, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 542.60 Cr, and the sum of Net Profit for the same period is 39.49 Cr. This data is based on Standalone financials.<BR><BR>Balance Sheet Snapshot: This is Standalone data for the latest annual period ending in March 2024. Shareholder's Funds are reported at 278.36 Cr, and Total Assets amount to 743.27 Cr.

Who are in the management team of Bajaj Healthcare?

As of March 2020, the management team of Bajaj Healthcare includes Sanjankumar R Bajaj (Chairman & Managing Director), Anil C Jain (Joint Managing Director), and several other directors and independent members responsible for the company's operations and strategy.

As of March 2020, the management team of Bajaj Healthcare includes the following individuals:<BR><BR>1. Sanjankumar R Bajaj - Chairman & Managing Director<BR>2. Anil C Jain - Joint Managing Director<BR>3. Namrata S Bajaj - Whole-time Director<BR>4. Dhananjay S Halte - Whole-time Director<BR>5. Rupesh H Nikam - Whole Time Director & CFO<BR>6. Ram B Banarase - Independent Director<BR>7. Hemant R Karnik - Independent Director<BR>8. Aakashkumar Kesari - Company Secretary<BR>9. Avinash Dalal - Independent Director<BR>10. Loukik D Tipnis - Independent Director<BR>11. Luke Benedict Fernandez - Independent Director<BR>12. Kejal Shah - Independent Director<BR>13. Pakshal Jain - Director<BR><BR>This team is responsible for overseeing the operations and strategic direction of the company.

When is the next results date for Bajaj Healthcare?

No Upcoming Board Meetings

What is the bonus history of the Bajaj Healthcare?

Bajaj Healthcare announced a 1:1 bonus issue on April 9, 2019, with a record date of April 10, 2019, granting shareholders one additional share for each share held.

Bajaj Healthcare has a bonus history that includes a 1:1 bonus issue announced on April 9, 2019. The record date for this bonus was April 10, 2019. This means that shareholders received one additional share for every share they held as of the record date.

Has Bajaj Healthcare declared dividend?

Yes, Bajaj Healthcare Ltd has declared a 20% dividend, amounting to ₹1 per share, with an ex-date of September 23, 2024. The company has shown strong total returns over various periods, including a 310.14% return over the last 5 years.

Bajaj Healthcare Ltd has declared a 20% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 20%<BR>- Amount per share: 1 per share<BR>- Ex-date: 23 Sep 24<BR><BR>Dividend Yield: 0.19%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, Bajaj Healthcare experienced a price return of 21.85%, with no dividend return, resulting in a total return of 21.85%.<BR><BR>Over the past year, the company saw a price return of 81.69% and a dividend return of 0.32%, leading to a total return of 82.01%.<BR><BR>In a 2-year period, the price return was 76.99%, with a dividend return of 0.64%, culminating in a total return of 77.63%.<BR><BR>For the 3-year period, the price return stood at 67.82%, while the dividend return was 1.26%, resulting in a total return of 69.08%.<BR><BR>In the 4-year timeframe, the price return was 36.62%, with a dividend return of 1.04%, leading to a total return of 37.66%.<BR><BR>Over the last 5 years, Bajaj Healthcare achieved a remarkable price return of 307.08% and a dividend return of 3.06%, resulting in a total return of 310.14%.<BR><BR>Overall, Bajaj Healthcare's dividend declaration reflects a commitment to returning value to shareholders, and the substantial total returns across various periods indicate strong performance and growth potential for the company.

Who are the peers of the Bajaj Healthcare?

Bajaj Healthcare's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, and others. In terms of performance, Bajaj Healthcare has a strong 1-year return of 85.57%, while its peers show varying management risks and growth rates.

Peers: The peers of Bajaj Healthcare are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Jagsonpal Pharma, Hester Bios, Bliss GVS Pharma, Themis Medicare, and Remus Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, while Average management risk is found at Jagsonpal Pharma, Hester Bios, Bliss GVS Pharma, Themis Medicare, and Remus Pharma. Growth is excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Bajaj Healthcare, Torrent Pharma, Hester Bios, Bliss GVS Pharma, and Themis Medicare show below average growth. Capital structure is excellent at Sun Pharma.Inds., Divi's Lab., Cipla, and Jagsonpal Pharma, while Bajaj Healthcare and Hester Bios have an average and below average capital structure, respectively.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.96%, while Themis Medicare has the lowest at -34.36%. Bajaj Healthcare's 1-year return of 85.57% is significantly higher than both. Additionally, Hester Bios, Themis Medicare, and Remus Pharma have negative six-month returns.

What does Bajaj Healthcare do?

Bajaj Healthcare Ltd is a small-cap bulk drug manufacturer in the Pharmaceuticals & Biotechnology industry, established in 1993 and publicly listed since 2016, with recent quarterly net sales of ₹1,545 Cr and a net profit of ₹112 Cr. Key financial metrics include a P/E ratio of 38.00 and a market cap of ₹1,704 Cr.

Overview:<BR>Bajaj Healthcare Ltd is a bulk drug manufacturer operating in the Pharmaceuticals & Biotechnology industry and classified as a Small Cap company.<BR><BR>History:<BR>Bajaj Healthcare Ltd was established in 1993 and became a public company in 2005. It listed its shares on the Indian stock exchanges in 2016. The latest quarterly results reported net sales and profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>Net Sales: 1,545 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 112 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: INR 1,704 Cr (Small Cap)<BR><BR>Key Metrics:<BR>P/E: 38.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.19% <BR>Debt Equity: 0.41 <BR>Return on Equity: 9.67% <BR>Price to Book: 3.79 <BR><BR>Contact Details:<BR>Address: 602-606 Bhoomi Velocity Infote, Road No 23 Wagle Indl Estate Thane Maharashtra : 400604 <BR>Tel: 91-22-66177400/401 <BR>Email: investors@bajajhealth.com <BR>Website: http://www.bajajhealth.com

Who are the top shareholders of the Bajaj Healthcare?

The top shareholders of Bajaj Healthcare include Sajankumar Rameshwarlal Bajaj with 37.59%, individual investors with 26.72%, and institutional investors, including mutual funds at 1.64% and foreign institutional investors at 1.05%. The largest public shareholder is Vanaja Sundar Iyer, holding 2.22% of the shares.

The top shareholders of Bajaj Healthcare include the promoters, with Sajankumar Rameshwarlal Bajaj holding the highest stake at 37.59%. Additionally, individual investors collectively own 26.72% of the shares. The company also has some institutional investment, with mutual funds holding 1.64% through one scheme and foreign institutional investors (FIIs) holding 1.05% across ten different entities. The highest public shareholder is Vanaja Sundar Iyer, who holds 2.22% of the shares.

Are Bajaj Healthcare latest results good or bad?

Bajaj Healthcare's latest Q2 FY26 results are generally positive, with a net profit growth of 49.28% year-on-year and improved operating margins at 18.21%. However, a slight revenue decline of 0.62% from the previous quarter suggests caution is warranted moving forward.

Bajaj Healthcare's latest results for Q2 FY26 can be considered good overall, despite some mixed signals. The company reported a net profit of ₹12.45 crore, which represents a significant year-on-year growth of 49.28%. This indicates a strong recovery from previous performance levels. Additionally, the operating margin improved to 18.21%, up 175 basis points from the previous quarter, showcasing effective cost management.<BR><BR>On the revenue side, the company achieved ₹147.91 crore, reflecting an 11.14% increase year-on-year. However, there was a slight decline of 0.62% compared to the previous quarter, suggesting that while demand has stabilized, it hasn't necessarily expanded in the short term.<BR><BR>Overall, the positive aspects of margin expansion and strong year-on-year profit growth suggest that Bajaj Healthcare is navigating its challenges effectively, making its latest results more favorable than unfavorable. However, investors should remain cautious about the slight revenue decline and monitor future performance closely.

Is Bajaj Healthcare overvalued or undervalued?

As of November 7, 2025, Bajaj Healthcare is considered overvalued with a PE ratio of 27.28, significantly higher than its peers like Cipla and Dr. Reddy's Labs, and has underperformed the Sensex with a year-to-date return of -24.7%.

As of 7 November 2025, Bajaj Healthcare's valuation grade has moved from fair to expensive, indicating a shift in its perceived market value. The company is currently overvalued based on its financial metrics. Key ratios include a PE ratio of 27.28, an EV to EBITDA of 18.91, and a PEG ratio of 0.83, which suggests that while the company is growing, its valuation may not be justified by its earnings growth prospects.<BR><BR>In comparison to its peers, Bajaj Healthcare's PE ratio is notably higher than Cipla's 22.33, which is rated attractive, and Dr. Reddy's Labs at 17.43, also attractive. This indicates that Bajaj Healthcare is trading at a premium relative to these competitors despite not offering a significantly better growth outlook. Additionally, the stock has underperformed against the Sensex in the year-to-date period, with a return of -24.7% compared to the Sensex's 6.50%, further reinforcing the notion that the stock may be overvalued in the current market environment.

How has been the historical performance of Bajaj Healthcare?

Bajaj Healthcare's historical performance has shown significant fluctuations, with net sales peaking at 645.80 Cr in Mar'23 but declining to 542.60 Cr by Mar'25, alongside decreases in profit metrics and cash flow, despite an increase in total assets. Overall, the company has faced both growth and challenges in its financial performance.

Answer:<BR>The historical performance of Bajaj Healthcare shows significant fluctuations in key financial metrics over the years.<BR><BR>Breakdown:<BR>Bajaj Healthcare's net sales have experienced variability, peaking at 645.80 Cr in Mar'23 before declining to 542.60 Cr in Mar'25. The total operating income followed a similar trend, with a high of 679.89 Cr in Mar'22 and a decrease to 542.60 Cr in Mar'25. Raw material costs rose from 291.33 Cr in Mar'19 to 307.11 Cr in Mar'25, while total expenditure, excluding depreciation, increased from 327.55 Cr in Mar'19 to 460.17 Cr in Mar'25. Operating profit (PBDIT) fluctuated, reaching a high of 143.23 Cr in Mar'21 but dropping to 101.83 Cr in Mar'25. Profit before tax saw a significant decline from 118.82 Cr in Mar'21 to 46.01 Cr in Mar'25, with profit after tax also decreasing from 83.11 Cr in Mar'21 to 42.93 Cr in Mar'25. The company's total assets increased from 342.95 Cr in Mar'20 to 814.15 Cr in Mar'25, while total liabilities rose from 182.57 Cr in Mar'21 to 272.27 Cr in Mar'25. Cash flow from operating activities showed a decline from 43.00 Cr in Mar'21 to 21.00 Cr in Mar'25, with net cash inflow remaining stable at 0.00 Cr in Mar'25. Overall, Bajaj Healthcare's financial performance reflects a mix of growth and challenges over the years.

Is Bajaj Healthcare technically bullish or bearish?

As of December 1, 2025, Bajaj Healthcare's technical trend has shifted to a moderate bearish stance, indicated by bearish MACD, Bollinger Bands, and moving averages, despite a mildly bullish KST signal on the weekly chart.

As of 1 December 2025, the technical trend has changed from mildly bearish to bearish. The current technical stance for Bajaj Healthcare is bearish with a moderate strength. Key indicators driving this stance include the bearish MACD on the weekly chart, bearish Bollinger Bands on both weekly and monthly time frames, and a bearish moving average on the daily chart. The KST shows a mildly bullish signal on the weekly but remains mildly bearish on the monthly, indicating some divergence. Overall, the lack of strong signals from the RSI and Dow Theory further supports the bearish outlook.

Should I buy, sell or hold Bajaj Healthcare Ltd?

Why is Bajaj Healthcare Ltd falling/rising?

As of 17-Mar, Bajaj Healthcare Ltd's stock price is declining, currently at Rs 278.15, with a 13.12% drop over the past week and significant underperformance compared to benchmarks and its sector. Despite recent positive financial results, weak long-term fundamentals and reduced investor interest are contributing to the stock's bearish trend.

As of 17-Mar, Bajaj Healthcare Ltd's stock price is falling, currently at Rs 278.15, reflecting a decrease of Rs 1.4 or 0.5%. The stock has been on a downward trend, having lost 13.12% over the last seven days and is now only 1.8% away from its 52-week low of Rs 273.15. This decline is further evidenced by the stock's performance against various benchmarks, showing a significant drop of 57.83% over the past year, compared to a 2.56% increase in the Sensex.<BR><BR>The stock is also underperforming its sector, with a performance today that is 0.78% lower than the sector average. Additionally, Bajaj Healthcare is trading below its moving averages across multiple time frames, indicating a bearish trend. Investor participation has decreased, with a delivery volume that has fallen by 27.48% against the five-day average, suggesting reduced interest from investors.<BR><BR>While the company has reported positive financial results in recent quarters, including a 22.82% growth in profit after tax and a 20.81% increase in net sales, these positive factors are overshadowed by the stock's weak long-term fundamentals. The company has experienced a -9.00% CAGR growth in operating profits over the last five years and has a high debt-to-EBITDA ratio of 2.59 times, indicating challenges in servicing its debt. Overall, the combination of poor recent performance, declining investor interest, and weak long-term fundamentals contributes to the ongoing decline in Bajaj Healthcare Ltd's stock price.

Why is Bajaj Healthcare Ltd falling/rising?

As of 18-Mar, Bajaj Healthcare Ltd's stock price is rising to 309.10, up 11.13% after a trend reversal following seven days of decline. Increased investor participation and a notable intraday high of Rs 313.9 indicate strong market sentiment.

As of 18-Mar, Bajaj Healthcare Ltd's stock price is rising, currently at 309.10, reflecting a change of 30.95 (11.13%) upward. This increase comes after a trend reversal, as the stock has gained after seven consecutive days of decline. Today, it has outperformed its sector by 10.86%. The stock reached an intraday high of Rs 313.9, indicating strong performance within the trading day.<BR><BR>Additionally, there has been a notable increase in investor participation, with delivery volume rising by 71.62% compared to the 5-day average. This suggests heightened interest from investors, contributing to the stock's upward movement. Despite the stock's recent volatility, with an intraday volatility of 5.34%, the current price reflects a positive shift in market sentiment towards Bajaj Healthcare Ltd.

Why is Bajaj Healthcare Ltd falling/rising?

As of 19-Mar, Bajaj Healthcare Ltd's stock price is currently at 301.50, reflecting a decline of 2.46%. The stock has underperformed its sector and has seen significant drops over the past month and year-to-date, indicating a negative trend despite increased investor participation.

As of 19-Mar, Bajaj Healthcare Ltd's stock price is falling, currently at 301.50, which reflects a decrease of 7.6 points or 2.46%. The stock opened the day with a significant loss of 4.48% and reached an intraday low of Rs 295.25. Additionally, the stock has underperformed its sector by 0.31%. Over the past month, the stock has declined by 15.42%, which is more than the Sensex's drop of 10.05%. Year-to-date, Bajaj Healthcare has seen a substantial decrease of 27.39%, compared to the Sensex's decline of 12.92%. <BR><BR>Despite a brief intraday high of Rs 320.95, the overall trend indicates a struggle, as the stock is trading lower than its 20-day, 50-day, 100-day, and 200-day moving averages, although it is higher than the 5-day moving average. The pharmaceuticals and drugs sector has also faced a decline of 2.13%, contributing to the negative sentiment surrounding the stock. While there has been a rise in investor participation, with a delivery volume increase of 150.52% on March 18, this has not translated into a positive price movement for Bajaj Healthcare Ltd.

Why is Bajaj Healthcare Ltd falling/rising?

As of 20-Mar, Bajaj Healthcare Ltd's stock price is rising to Rs 313.45, up 3.64%, despite a -55.72% decline over the past year. Recent positive financial results indicate growth in profit and sales, but long-term fundamentals remain weak, raising concerns about future performance.

As of 20-Mar, Bajaj Healthcare Ltd's stock price is rising, currently at Rs 313.45, reflecting an increase of Rs 11.0 or 3.64%. This upward movement is supported by the stock's performance today, where it outperformed its sector by 1.26% and reached an intraday high of Rs 315.7, which is a 4.38% increase. <BR><BR>Despite a significant decline in the stock's value over the past year, with a return of -55.72%, the company has reported positive financial results for the last three consecutive quarters. Notably, the profit after tax (PAT) for the last nine months grew by 22.82%, and net sales for the latest six months increased by 20.81%. Additionally, the company has a strong operating profit to interest ratio, which is the highest at 5.22 times, indicating solid operational performance relative to its debt obligations.<BR><BR>However, it is important to note that while the stock is currently rising, it has been characterized by weak long-term fundamentals, including a -9.00% compound annual growth rate (CAGR) in operating profits over the last five years and a high debt to EBITDA ratio of 2.59 times. This suggests that despite the recent positive performance, the stock's long-term outlook remains concerning, which could affect future price movements.

Why is Bajaj Healthcare Ltd falling/rising?

As of 23-Mar, Bajaj Healthcare Ltd's stock price is declining, currently at 304.50, with a year-to-date drop of -26.67% and a significant annual decline of -57.04%. This downturn is attributed to poor long-term performance, decreasing investor participation, and challenges within the Pharmaceuticals & Drugs sector.

As of 23-Mar, Bajaj Healthcare Ltd's stock price is falling, currently at 304.50, reflecting a change of -8.95 (-2.86%). The stock opened the day with a loss of -2.57% and reached an intraday low of Rs 296, which is a decrease of -5.57%. This decline is occurring despite the stock outperforming its sector by 1.24% today. <BR><BR>Over the past week, the stock has shown a positive return of +8.93%, contrasting with the Sensex's decline of -3.72%. However, the longer-term performance reveals significant challenges, with a year-to-date decline of -26.67% compared to the Sensex's -14.70%. Additionally, the stock has experienced a substantial drop of -57.04% over the past year, while the Sensex has only fallen by -5.47% during the same period.<BR><BR>Investor participation appears to be decreasing, as evidenced by a delivery volume of 2.15 lacs on 20 March, which is down by -25.04% against the 5-day average delivery volume. The overall sector, Pharmaceuticals & Drugs, has also faced a decline of -3.58%, which may be contributing to the negative sentiment surrounding Bajaj Healthcare Ltd. Furthermore, the stock's moving averages indicate that it is currently lower than the 20-day, 50-day, 100-day, and 200-day moving averages, suggesting a bearish trend. <BR><BR>In summary, the combination of poor long-term performance, decreasing investor participation, and a struggling sector are key factors contributing to the decline in Bajaj Healthcare Ltd's stock price.

Why is Bajaj Healthcare Ltd falling/rising?

As of 24-Mar, Bajaj Healthcare Ltd's stock price is at 305.00, showing a minor increase but significant long-term underperformance with a 56.12% decline over the past year and high debt levels. Despite recent profit growth, the stock is trading at a discount and faces reduced investor interest.

As of 24-Mar, Bajaj Healthcare Ltd's stock price is currently at 305.00, reflecting a slight increase of 0.5 (0.16%). Despite this minor rise, the stock has shown significant underperformance over various time periods. In the past week, it has increased by 9.65%, contrasting sharply with the Sensex, which has declined by 2.63%. However, over the last month, the stock has dropped by 10.81%, and year-to-date, it has fallen by 26.55%. <BR><BR>The stock's long-term performance is concerning, with a staggering decline of 56.12% over the past year and a negative compound annual growth rate (CAGR) of 9.00% in operating profits over the last five years. This indicates weak long-term fundamental strength. Additionally, the company has a high Debt to EBITDA ratio of 2.59 times, suggesting a low ability to service its debt, which could deter investors.<BR><BR>On a more positive note, the company has reported strong results in the last three consecutive quarters, with a profit after tax (PAT) growth of 22.82% and record net sales of Rs 161.22 crore. Despite these positive results, the stock is trading at a significant discount compared to its peers, and its performance has been below par in both the long and near term.<BR><BR>Investor participation has also declined, with delivery volume falling by 48.17% against the five-day average, indicating reduced interest from investors. Overall, while there is a slight uptick in the stock price today, the broader context of declining performance, high debt levels, and reduced investor engagement suggests that the stock is facing significant challenges.

Why is Bajaj Healthcare Ltd falling/rising?

As of 25-Mar, Bajaj Healthcare Ltd's stock price is currently at 310.95, showing a recent upward trend but has underperformed its sector and declined significantly over the past month and year. Investor participation is decreasing, which may affect future price movements despite the recent gains.

As of 25-Mar, Bajaj Healthcare Ltd's stock price is rising, currently at 310.95, reflecting a change of 3.6 (1.17%) upward. The stock has shown consecutive gains over the last two days, with a total increase of 2.12% during this period. Additionally, the stock reached an intraday high of Rs 326.45, which is a significant rise of 6.21%. <BR><BR>Despite this recent upward movement, it is important to note that the stock has underperformed its sector by 0.72% today and has experienced a decline of 9.20% over the past month. Year-to-date, the stock is down 25.12%, and over the last year, it has fallen by 56.22%. The current price is also higher than the 5-day moving averages, although it remains lower than the 20-day, 50-day, 100-day, and 200-day moving averages, indicating mixed performance in the context of longer-term trends.<BR><BR>Investor participation has decreased, with a delivery volume of 1.02 lacs on 24 March, which is down 64.37% compared to the 5-day average. This decline in participation could impact future price movements. Overall, while the stock is currently rising, it faces significant challenges from its recent performance metrics and declining investor interest.

Which are the latest news on Bajaj Healthcare?